ProjectONE plan approved
Architectural rendering of ProjectONE’s proposed 17-story tower that will house the new cancer hospital plus a critical care hospital and outpatient and support facilities.
In September, The Ohio State University Board of Trustees approved architecture and construction plans for ProjectONE, a $1 billion expansion project that will include a 17-story tower to house a new 276-bed James Cancer Hospital and Solove Research Institute spread over seven floors.
The tower also will hold a new five- floor, 144-bed critical care hospital. The remaining five floors will contain outpatient and support services.
ProjectONE is one of the largest job-generating initiatives in Ohio’s history.
“The new configuration and technologically advanced facilities will ease collaborations among researchers, physicians and patients, reshaping hands-on care and making possible transfor-mational discoveries, therapies and treatments,” says Ohio State President E. Gordon Gee.
A new hospital is needed because inpatient admissions at The James are expected to grow by 21 percent over the next 10 years. “The James’ expansion is critical to those seeking the latest advancements in diagnosis and treatment,” says James CEO Michael Caligiuri, MD, who also directs Ohio State’s Comprehensive Cancer Center.
“ProjectONE’s state-of-the-art facilities will give scientists, researchers and clinicians the environment they need to collaborate and solve critical and complex health-related issues,” Caligiuri says.
Supporting clinical correlative research
The Clinical Treatment Unit and the Clinical Trials Processing Laboratory (CTU/CTPL) Shared Resources provide support to investigators conducting phase I and phase II clinical translational research studies at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
The CTU is an outpatient, phase I clinical trial unit at The James that treats patients who require intense monitoring or complex correlative sample collection and processing. The CTPL specializes in procuring correlative research specimens from the CTU and from the hospital’s inpatient care areas, and processing, storing and shipping them to outside laboratories.
“By working with the CTU and CTLP, clinical investigators can improve protocol compliance by freeing up research nurses and coordinators to focus on other protocol-related activities,” says director Larry J. Schaaf, PhD, an adjunct professor in The Ohio State University College of Pharmacy who has more than 20 years experience conducting and analyzing phase I and phase II clinical correlative trials.
“In addition, all of our staff are trained in protocol specimen requirements.”
Between January 2004 and December 2008, the laboratory procured 26,634 specimens. During 2008, the CTU/CTPL activities included the following:
• Supporting 82 therapeutic trials
• Procuring 7,983 specimens
• Shipping 1,108 sample sets, all according to IATA Dangerous Goods and DOT regulations.
RIDE WRAP UP
Pelotonia ’09 Raises more than $4.5 million for cancer research at the OSUCCC–James
The 2,265 cyclists who participated in the inaugural Pelotonia bicycling excursion came from 31 states and Canada. The youngest rider was 11 and the oldest was 77, and they included renowned cycling champion and honorary chair Lance Armstrong. Together, they raised $4,511,868.42, every penny of which is supporting cancer research at the Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute.
Pelotonia’s riders were greeted by an outpouring of support along the route between Columbus and Athens in southern Ohio during the weekend of Aug. 28-30. More than 1,000 volunteers assisted the riders along the way.
“The feeling of achievement is incredibly addictive,” says Tom Lennox, executive director of Pelotonia. “This was our first Pelotonia, and although we were optimistic about the success of the event, we are even more pleased with the outcome. We are looking forward to making Pelotonia 10 an even bigger success.”
Many riders said they would ride again and bring friends and family to join them in the 2010 Pelotonia, scheduled for Aug. 13-15. Registration opened Dec. 1, 2009.
“Each and every one of us has been affected by cancer in some way, and we all want to take the battle into our own hands,” says E. Gordon Gee, president of The Ohio State University. “Pelotonia gives us that chance. The inaugural ride’s remarkable success testifies to the tremendous partnership among individuals, communities, corporations, and the University.”
Gee noted “the very real ways in which the funds raised enable our physicians and researchers to improve the lives of patients and their families.”
“We need a world that’s cancer-free,” says OSUCCC Director and James CEO Michael A. Caligiuri, MD. “And because of Pelotonia, we have additional, much-needed funding resources that will help prevent, detect, diagnose and treat cancers.”
Pelotonia Payoff – Pelotonia representatives present a check for more than $4.5 million to Ohio State University officials in Ohio Stadium on Oct. 31. The money will support cancer research at Ohio State’s Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute. Representing Pelotonia are (from left) Andy Hutter, Kelley Griesmer, Jessica Kinman and Executive Director Tom Lennox. Holding the check are (from left) Ohio State University President E. Gordon Gee, OSUCCC Director and James CEO Michael A. Caligiuri, MD, and Peter Weiler, senior vice president for university development and president of The Ohio State University Foundation.